gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BIIBHealthcareBiotechnology

Biogen Inc. Common Stock (BIIB)

$254.46+2.22%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$248.93▲ 64.38% in range
Nov 3, 2025Low $149.33 · High $253.84Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Biogen closed at $254.46 on Nov 4, up 2.22% — matching its 52-week closing high. Volume of 1.3M shares was 0.99× its 20-day average (close to normal).

Split-adjusted performance: +14.2% over one month, +33.4% over six months, +68.0% over one year.

In the quarter ended Sep 30, 2026, revenue was $2.80B, up 10.6% from a year earlier, with a net margin of -0.7%.

Short interest was 5.5M shares at the Oct 15 settlement, down 7.8% from the prior report (3.7% of float, 4.4 days to cover).

Market cap$37.61B147.8M shares
Revenue · quarter$2.80B+10.6% YoY
Diluted EPS$-0.14−104.4% YoY
P/E · TTM108.2×P/S 3.7×
Net margin-0.7%Gross 73.3%
Dividend yieldNone
52-week range149.33 – 254.460.0% from high
Volume1.3M0.99× 20-day avg
Volatility · 60d28.2%Annualised
Short % of float3.7%4.4 days to cover
Net cash-$6.39BCash $1.30B
Next earnings—Not scheduled
Split-adjusted performance
1W +4.3%1M +14.2%3M +23.4%6M +33.4%YTD +44.6%1Y +68.0%3Y +7.3%5Y −2.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum84
Revenue growth57
Net margin74
Value (low P/E)0
Size97

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short5.5M−7.8% vs prior
Days to cover4.4Settled Oct 15
% of float3.7%
Short vol. 10d60.5%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BIIBBiogen$254.46+2.22%+33.4%+10.6%−0.7%108.2$37.61B
RVMDRevolution Medicines$199.70+2.82%+32.2%———$42.80BCompare
EXELExelixis$72.75+0.61%+49.4%+10.2%33.1%20.1$17.75BCompare
NBIXNeurocrine Biosciences$166.05+0.73%+12.9%+41.2%18.4%24.0$16.88BCompare
HALOHalozyme Therapeutics$130.34+1.34%+96.4%+47.7%47.8%35.8$14.79BCompare
MRNAModerna$258.38+13.11%+429.6%+2.1%−539.3%—$103.15BCompare
KYMRKymera Therapeutics$136.25+7.21%+58.0%−100.0%——$11.63BCompare
TECHBio-Techne$72.73+0.10%+53.4%+1.3%17.0%62.8$11.42BCompare
RGENRepligen$178.20−0.04%+41.7%+10.9%−18.4%—$11.31BCompare

News about Biogen

All news →
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View TightenedZacks Investment Research · Oct 28, 2026▲ PositiveBiogen Inc. (BIIB) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research · Oct 28, 2026NeutralBiogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?Zacks Investment Research · Oct 23, 2026NeutralBiogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research · Oct 21, 2026▲ PositiveWill Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research · Oct 6, 2026▲ Positive

Quick answers

What does Biogen do?
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025.
What is BIIB's market cap?
$37.61B, based on the Nov 4 close of $254.46.
What is BIIB's P/E ratio?
108.2× trailing-twelve-month earnings of $347.50M.
Does Biogen pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BIIB is sold short?
5.5M shares, 3.7% of float, as of Oct 15, 2026.
What sector is BIIB in?
Healthcare, in the Biotechnology industry.

About Biogen

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

HQ: Cambridge, MA7,500 employeesListed Sep 17, 1991biogen.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology